Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$71.32M+12.3%$63.49M+12.8%$56.3M+4.9%$53.69M+23.2%$43.58M+5.4%
$21.72M+5.7%$20.55M+1.7%$20.21M-1.7%$20.56M+4.0%$19.76M+18.7%
$93.04M+10.7%$84.04M+9.8%$76.51M+3.0%$74.26M+17.2%$63.35M+9.2%
-$93.04M-10.7%-$84.04M-9.8%-$76.51M-3.0%-$74.26M-17.2%-$63.35M-9.2%
$51K-19.0%$63K-13.7%$73K-13.1%$84K-11.6%$95K-10.4%
$10.78M-3.0%$11.12M+9.1%$10.19M+10.1%$9.25M+97.7%$4.68M+13,271%
-$72.92M-9.9%-$66.32M-2.0%-$65M-10.8%-$58.67M-1.2%
$26.43M+54.2%$17.14M+1.5%$16.89M0.0%$16.89M+6.1%$15.91M+4.2%
-$83.49M-12.6%-$74.15M-10.2%-$67.3M-2.0%-$65.98M-12.5%-$58.67M-1.2%
-$4.46-10.1%-$4.05
-$91.72M-11.0%-$82.66M-10.3%-$74.96M-3.2%-$72.63M-17.7%-$61.72M-9.5%
-$93.04M-10.7%-$84.04M-9.8%-$76.51M-3.0%-$74.26M-17.2%-$63.35M-9.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Tectonic Therapeutics profitable?
Tectonic Therapeutics is not currently profitable: it reported a net loss of $83.5M over the trailing twelve months.
What is Tectonic Therapeutics's earnings per share?
Tectonic Therapeutics's diluted EPS over the trailing twelve months is $-4.46.
Where does Tectonic Therapeutics's income statement data come from?
Every line is extracted from Tectonic Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.